#mndwarrior #mndefiance #mnd #motorneuronediseaseawareness #mndawareness #als #alsawareness #mndfeminabellator #googlemnd💙🧡💙🧡 #Proleukin

Now is the time!!!! 😡 Release the paper and help us access Proleukin!!!!!

proleukin (aldesleukin). earliest submission - 1992, chiron corporation (affiliate of glaxosmithkline). 31 death related events.

$IOVA (per Dan): Q4’s stacked—tons of new ATCs, Proleukin sales gonna pop (peep last year’s Q4 numbers), and ATCs are booming everywhere (community + academia).

$IOVA- Expecting significant revenue from Proleukin in 2024. In order for immunotherapy to work, the patients also needed to be infused with IL-2 to boost the strength of Killer T cells. $IOVA has worldwide patent with Proleukin. They will sell this product to companies doing

$HOWL has a clean safety, the same as $MDNAF, both step up from the toxic drug Proleukin IL-2

Proleukin could be a game changer for people with #MND. They need access on the NHS. Please don’t let it get caught up in the bureaucracy. Great to meet Lee @onein300 and Dave @dsetters . We are all #United2EndMND

$IOVA Q2 '25: Rev: $60m (+93% YoY), Amtagvi $54.1m, Proleukin $5.9m >100 patients treated w/Amtagvi in Q2, 80+ US ATCs across 35 states Strategic restructuring extends cash runway into Q4'26 FY25 guidance: $250-300m total product rev PR: https://t.co/hvmVi3K20p

PREPARATION is all @MNDpatients @mndassoc @MNDoddie5 @MNDScotland @mndresearch scientists must PREPARE for hoped for +ve outcome of #Mirocals trial. Without further evidence #Iltoo product is a non-runner for immediate future. Let's PREPARE for #Proleukin https://t.co/ejwPZAyHCq

$IOVA catalysts and cash ended 1Q24 with $362.6mm in cash mgt . reiterated cash runway guidance (inclusive of 2024 revenue estimates for Amtagvi and Proleukin) into the 2H25.

We advised #biotechnology company @IovanceBio in its definitive agreement with @Clinigen Limited to acquire Proleukin® for approximately US$200 million upon closing, US$50 million milestone payment and additional deferred consideration payments. https://t.co/006FoymEki

$IOVA Iovance Biotherapeutics, Inc. Earnings Call Key Highlights: 💵 Robust Financial Performance and Revenue Guidance Q3 2024 revenue totaled $58.6 million, including $42.1 million from Amtagvi and $16.5 million from Proleukin, surpassing the upper end of prior guidance.

$IOVA Iovance Biotherapeutics, Inc. Q4 2024 Earnings Call Key Highlights: 💰 Financial Performance: Q4 2024 Revenue: $73.7 million, driven by $48.7 million from Amtagvi and $25.0 million from Proleukin. Full Year 2024 Revenue: $164.1 million, achieving the upper end of guidance

This clearly shows #Mirocals results expected by end March 23. WHY the delay? We're not demanding access to #Proleukin We know we need results. TRANSPARENCY is a MUST for CHARITY funded trial. @MNDPatients, pls ask @mndassoc for answers to our 6 questions https://t.co/lHq5EukdAv

$IOVA #Iovance has NEW #Buy rating due to combination of factors including successful launch of Iovance Biotherapeutics’s new treatment, #Amtagvi, which has shown strong initial momentum. Expected revenue from both Amtagvi + another product #Proleukin. #HotStocks #BeatCancer

#proleukin #mirocal consortium give us a date!

$IOVA - Q3 2024 was their best quarter with high Proleukin restocking from vendors. If Q3 shows great results combined with increased Amtagvi infusions and Proleukin restocking, it will be deadly for shorts. The company already showed a 22% increase from Q1 to Q2. I am expecting

.@mndassoc #Mirocals Q of The Day 7/7 Will you meet @IovanceBio owner of #Proleukin drug used in trial as @united2endmnd suggest? With no clear answers from #Iltoo your duty to @MNDPatients is to prepare for quick access if results are +VE. Or do commercial contracts stop you?

I was seriously wrong on this prediction (before the fireside chat) A major flop is the attrition rate. Historically the attrition cost is 15%. For 25Q1, this value inflates to an astonishing 26%😑 it is not a simple iCTC maintenance. Proleukin sales also dropped significantly.